These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31241282)

  • 1. Chronic hepatitis C in the Czech Republic: Forecasting the disease burden.
    Fraňková S; Urbánek P; Husa P; Němeček V; Razavi H; Razavi-Shearer D; Chlíbek R; Šperl J
    Cent Eur J Public Health; 2019 Jun; 27(2):93-98. PubMed ID: 31241282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
    Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
    Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
    Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
    J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Burden of disease and cost of chronic hepatitis C infection in Canada.
    Myers RP; Krajden M; Bilodeau M; Kaita K; Marotta P; Peltekian K; Ramji A; Estes C; Razavi H; Sherman M
    Can J Gastroenterol Hepatol; 2014 May; 28(5):243-50. PubMed ID: 24839620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology, disease burden, and treatment strategies of chronic hepatitis C virus infections in Saudi Arabia in the new treatment paradigm shift.
    Aljumah AA; Abaalkhail F; Al-Ashgar H; Assiri A; Babatin M; Al Faleh F; Alghamdi A; Al-Hakeem R; Hashim A; Alqutub A; Razavi H; Sanai FM; Al-Swat K; Schmelzer J; Altraif I
    Saudi J Gastroenterol; 2016; 22(4):269-81. PubMed ID: 27488321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality.
    Cramp ME; Rosenberg WM; Ryder SD; Blach S; Parkes J
    BMC Gastroenterol; 2014 Aug; 14():137. PubMed ID: 25100159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of improved treatment on disease burden of chronic hepatitis C in New Zealand.
    Gane E; Stedman C; Brunton C; Radke S; Henderson C; Estes C; Razavi H
    N Z Med J; 2014 Dec; 127(1407):61-74. PubMed ID: 25530333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan.
    Younossi ZM; Tanaka A; Eguchi Y; Henry L; Beckerman R; Mizokami M
    J Viral Hepat; 2018 Aug; 25(8):945-951. PubMed ID: 29478258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimates on HCV disease burden worldwide - filling the gaps.
    Wedemeyer H; Dore GJ; Ward JW
    J Viral Hepat; 2015 Jan; 22 Suppl 1():1-5. PubMed ID: 25560838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
    Carrat F; Fontaine H; Dorival C; Simony M; Diallo A; Hezode C; De Ledinghen V; Larrey D; Haour G; Bronowicki JP; Zoulim F; Asselah T; Marcellin P; Thabut D; Leroy V; Tran A; Habersetzer F; Samuel D; Guyader D; Chazouilleres O; Mathurin P; Metivier S; Alric L; Riachi G; Gournay J; Abergel A; Cales P; Ganne N; Loustaud-Ratti V; D'Alteroche L; Causse X; Geist C; Minello A; Rosa I; Gelu-Simeon M; Portal I; Raffi F; Bourliere M; Pol S;
    Lancet; 2019 Apr; 393(10179):1453-1464. PubMed ID: 30765123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Forecasting the disease burden of chronic hepatitis C virus in Poland.
    Flisiak R; Halota W; Tomasiewicz K; Kostrzewska K; Razavi HA; Gower EE
    Eur J Gastroenterol Hepatol; 2015 Jan; 27(1):70-6. PubMed ID: 25426979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
    Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
    Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward).
    Dore GJ; Ward J; Thursz M
    J Viral Hepat; 2014 May; 21 Suppl 1():1-4. PubMed ID: 24713003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease burden of chronic hepatitis C in Brazil.
    Ferreira PR; Brandão-Mello CE; Estes C; Gonçales Júnior FL; Coelho HS; Razavi H; Cheinquer H; Wolff FH; Ferraz ML; Pessoa MG; Mendes-Correa MC
    Braz J Infect Dis; 2015; 19(4):363-8. PubMed ID: 26051505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The estimated future disease burden of hepatitis C virus in the Netherlands with different treatment paradigms.
    Willemse SB; Razavi-Shearer D; Zuure FR; Veldhuijzen IK; Croes EA; van der Meer AJ; van Santen DK; de Vree JM; de Knegt RJ; Zaaijer HL; Reesink HW; Prins M; Razavi H
    Neth J Med; 2015 Nov; 73(9):417-31. PubMed ID: 26582807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios.
    Harris RJ; Thomas B; Griffiths J; Costella A; Chapman R; Ramsay M; De Angelis D; Harris HE
    J Hepatol; 2014 Sep; 61(3):530-7. PubMed ID: 24824282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Incidence of and Surveillance Burden for Hepatocellular Carcinoma Among Patients With Hepatitis C in the Era of Direct-Acting Antiviral Agents.
    Chen Q; Ayer T; Adee MG; Wang X; Kanwal F; Chhatwal J
    JAMA Netw Open; 2020 Nov; 3(11):e2021173. PubMed ID: 33206188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health care costs associated with chronic hepatitis C virus infection in Ontario, Canada: a retrospective cohort study.
    Wong WWL; Haines A; Bremner KE; Yao Z; Calzavara A; Mitsakakis N; Kwong JC; Sander B; Thein HH; Krahn MD
    CMAJ Open; 2021; 9(1):E167-E174. PubMed ID: 33688024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States.
    Durham DP; Skrip LA; Bruce RD; Vilarinho S; Elbasha EH; Galvani AP; Townsend JP
    Clin Infect Dis; 2016 Feb; 62(3):298-304. PubMed ID: 26628566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.